CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted
Drug / intervention
APOE Genetic susceptibility testingprocedure
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00089882
NCT00089882N/ACompleted
CompareCT.gov

Risk Evaluation and Education for Alzheimer's Disease (REVEAL) II

National Institute on Aging (NIA)·observational·Posted Aug 18, 2004·Updated Jul 23, 2009

In Brief

An observational study evaluating APOE Genetic susceptibility testing for Alzheimer Disease. Completed, across 4 sites.

Detailed Summary

The REVEAL II study provides healthy adult children and siblings of Alzheimer's disease patients with genetic testing and information about their own chances of developing the disease. The study will compare a condensed education and counseling program to the current more extensive program.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsAlzheimer Disease
CountriesUnited States
CollaboratorsNational Human Genome Research Institute (NHGRI)

Timeline

N/ACompletedFinished
2003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 18, 2004
Enrollment StartMay 1, 2003
Primary CompletionSep 1, 2006
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 21.9 years ago

Interventions

APOE Genetic susceptibility testingprocedure